UNASSIGNED: @entity5 are one of the three major causes of @entity8 with a functioning graft after @entity65 and @entity281 . Among the variety of risk factors, including conventional and specific to transplant recipients, the duration of immunosuppressive therapy, the intensity of therapy, and the type of immunosuppressive agent all have an impact on development of post-transplant @entity5 . The aim of our retrospective study was to document the incidence, the type of @entity5 , the @entity1 /graft survival in the group of kidney transplant recipients in Slovak Republic, and to identify the factors which influenced the outcome. We analyzed the data of 1421 @entity1 who underwent renal transplantation from deceased or living donors in the period from 2007 to 2015 in the Slovak transplant centers. The incidence of @entity5 was 6%, the @entity5 was diagnosed in 85 @entity1 at the age of 54.1    9.8 years, more frequently in @entity1 (68.2 %; P < 0.0001). The mean time of @entity5 occurrence was 45 months after transplantation. The most frequent @entity5 were @entity5 (BCC) in 17.6%, @entity957 ( @entity957 ) in 8.2%, and @entity320 ( @entity320 ) in 2.4% of @entity1 , followed by @entity1489 such as @entity1358 ( @entity1358 ) in 16.5%, @entity694 in 12.9%, @entity263 in 9.4%, @entity0 in 9.4%, @entity2 in 7.1%, @entity1071 ( @entity1071 ) in 2.4%, @entity5 of urine bladder in 2.4%, and @entity5 of sublingual gland in 1.17% of @entity1 . Surgical treatment was used in 40% of @entity1 , chemotherapy in 7.1%, radiotherapy in 2.4%, treatment with biological agents in 15.3%, combined therapy in 29.4% and palliative treatment in 5.9% of @entity1 . 55.3% of @entity1 underwent conversion from other immunosuppressive agents into mTORi at the time of @entity5 occurrence. The remission was achieved in 48.2% of @entity1 , 28.2% of @entity1 were in the oncology treatment in the end of the year 2015, and 23.5% of @entity1 died. There was no difference in the kidney function at the time of @entity5 occurrence (s-creat 133.7    59.8   mol/l) and one year later (s-creat 131.1    47.9   mol/l) (P = 0.7768). The @entity1 after successful treatment more frequently suffered from BCC (P = 0.0140), did not undergo palliative treatment (P = 0.0033), but were more frequently treated surgically (P < 0.0001).

Occurrence of XXXX after kidney transplantation in adults: Slovak multicenter experience.

@entity1 :: ('9606', 'Species') :: ['men', 'patient', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal recipient  s death'] @entity320 :: ('MESH:D008545', 'Disease') :: ['MM', 'malignant melanoma'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostatic cancer'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['post-transplant lymphoproliferative disease', 'PTLD'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Malignancies', 'malignancies', 'cancer', 'skin cancers- basal cell carcinoma', 'malignant tumors', 'malignancy'] @entity1489 :: ('MESH:D012878', 'Disease') :: ['non-skin tumors'] @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma', 'SCC'] @entity2 :: ('MESH:D008175', 'Disease') :: ['cancer of lung'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['renal cell carcinoma', 'RCC'] @entity694 :: ('MESH:D003110', 'Disease') :: ['cancer of colon'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']
@entity5 :: (MESH:D009369,Disease) :: ['malignancies']
